Evidence map›Paper›PMID 30834611›Full record

Trial reportJournal of cardiovascular electrophysiology2019

How to implant a phrenic nerve stimulator for treatment of central sleep apnea?

Ralph S Augostini, Muhammad R Afzal, Maria Rosa Costanzo, Randy Westlund, Christoph Stellbrink, Klaus Gutleben, Sanjaya Gupta, Moeen Saleem, Timothy W Smith, Michael Peterson and 6 more

Open access · hybridAbstract readRandomized Controlled TrialVideo-Audio Media
In one paragraph

Trial report in Journal of cardiovascular electrophysiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 26 citations in OpenAlex.

  1. Automatic activation of neurostimulation for central sleep apnea results in high nightly usage.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2026
    Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 3 countries.

Ralph S AugostiniThe Ohio State University Wexner Medical Center, Columbus, Ohio.ORCID 0000-0003-0006-2191
Muhammad R AfzalThe Ohio State University Wexner Medical Center, Columbus, Ohio.ORCID 0000-0002-3343-7618
Maria Rosa CostanzoAdvocate Heart Institute, Chicago, Illinois.
Randy WestlundRespicardia Inc, Minnetonka, Minnesota.
Christoph StellbrinkKlinikum Bielefeld, Bielefeld, Delaware.
Klaus GutlebenRuhruniversität Bochum, Bad Oeynhausen, Delaware.
Sanjaya GuptaDepartment of Cardiology, University of Missouri-Kansas City School of Medicine, Saint Luke's Mid-America Heart Institute, Kansas City, Missouri.
Moeen SaleemAdvocate Heart Institute, Chicago, Illinois.
Timothy W SmithWashington University School of Medicine, St Louis, Missouri.
Michael PetersonUnited Heart and Vascular Clinic, St Paul, Minnesota.
Michael DruckerNovant Health Cardiology, Winston-Salem, North Carolina.
Andrew MerlissBryan Medical Center, Lincoln, Nebraska.
John HayesMarshfield Clinic, Marshfield, Wisconsin.
Christen ButterHeart Center Brandenburg in Bernau/Berlin & Brandenburg Medical School, Bernau, Delaware.
Matthew HutchinsonUniversity of Arizona College of Medicine, Tucson, Arizona.ORCID 0000-0002-8286-0113
Dariusz Jagielski4th Military Hospital, Wroclaw, Poland.ORCID 0000-0002-3066-4030
Advocate Heart Institute · USThe Ohio State University Wexner Medical Center · USBryan Health · USCoskata (United States) · USKlinikum Bielefeld · DEMarshfield Clinic · USMilitary Hospital · PKNovant Health · USSaint Luke's Hospital · USUnited Heart and Vascular Clinic · USUniversity of Arizona · USWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCentral sleep apnea (CSA) is a breathing disorder caused by the intermittent absence of central respiratory drive. Transvenous phrenic nerve stimulation is a new therapeutic option, recently approved by the FDA , for the treatment of CSA.

objectiveTo describe the technique used to implant the transvenous phrenic nerve stimulation system (the remedē System, Respicardia, Inc).

methodsThe remedē System is placed in the pectoral region, typically on the right side. A single stimulation lead is placed in either the left pericardiophrenic vein (PPV) or the right brachiocephalic vein (RBC). A sensing lead is placed into the azygous vein to detect respiration.

resultsIn the remedē System Pivotal trial, 147 of 151 (97%) patients were successfully implanted with the system. Sixty-two percent of stimulation leads were placed in the PPV and 35% in the RBC. Mean procedure time was 2.7 ± 0.8 hours and 94% of patients were free from implant-related serious adverse events through 6 months.

conclusionIn patients with CSA, transvenous phrenic nerve stimulation is an effective and safe therapy with an implant procedure similar to that of cardiac implantable electronic devices.

Indexed as

Implantable NeurostimulatorsProsthesis ImplantationRespirationDiaphragmElectric Stimulation TherapyHumansOperative TimePhrenic NerveProsthesis DesignSleep Apnea, CentralTime FactorsTreatment Outcomecentral sleep apneaphrenic nervephrenic nerve stimulationtransvenous stimulation

Identifiers

PMID30834611
PMCPMC6850096
OpenAlexW2918265779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.